Protagonist Therapeutics PTGX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Protagonist Therapeutics (PTGX) reported accretion (amortization) of discounts and premiums, investments of $1.03M in Q1 2026.
- How has Protagonist Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Protagonist Therapeutics's accretion (amortization) of discounts and premiums, investments decreased by 55.2% year-over-year, from $2.29M to $1.03M.
- What is the long-term trend for Protagonist Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Protagonist Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 41.0% compound annual growth rate (CAGR), from -$1.83M to $7.22M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This reflects the periodic adjustment to the carrying value of investment securities to account for the amortization of premiums or accretion of discounts. It represents the non-cash portion of interest income or expense recognized over the life of the investment. This metric is essential for adjusting net income to reflect actual cash generated from investment portfolios.